1. Home
  2. AAPG vs TMDX Comparison

AAPG vs TMDX Comparison

Compare AAPG & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AAPG
  • TMDX
  • Stock Information
  • Founded
  • AAPG 2009
  • TMDX 1998
  • Country
  • AAPG China
  • TMDX United States
  • Employees
  • AAPG N/A
  • TMDX N/A
  • Industry
  • AAPG Biotechnology: Pharmaceutical Preparations
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • AAPG Health Care
  • TMDX Health Care
  • Exchange
  • AAPG Nasdaq
  • TMDX Nasdaq
  • Market Cap
  • AAPG 3.6B
  • TMDX 4.0B
  • IPO Year
  • AAPG 2025
  • TMDX 2019
  • Fundamental
  • Price
  • AAPG $32.00
  • TMDX $121.80
  • Analyst Decision
  • AAPG Buy
  • TMDX Buy
  • Analyst Count
  • AAPG 2
  • TMDX 11
  • Target Price
  • AAPG $48.00
  • TMDX $130.73
  • AVG Volume (30 Days)
  • AAPG 8.5K
  • TMDX 1.1M
  • Earning Date
  • AAPG 11-19-2025
  • TMDX 10-29-2025
  • Dividend Yield
  • AAPG N/A
  • TMDX N/A
  • EPS Growth
  • AAPG N/A
  • TMDX 170.70
  • EPS
  • AAPG N/A
  • TMDX 2.54
  • Revenue
  • AAPG $54,524,554.00
  • TMDX $566,354,000.00
  • Revenue This Year
  • AAPG N/A
  • TMDX $38.84
  • Revenue Next Year
  • AAPG $368.64
  • TMDX $20.46
  • P/E Ratio
  • AAPG N/A
  • TMDX $49.28
  • Revenue Growth
  • AAPG N/A
  • TMDX 41.20
  • 52 Week Low
  • AAPG $16.50
  • TMDX $55.00
  • 52 Week High
  • AAPG $48.45
  • TMDX $145.50
  • Technical
  • Relative Strength Index (RSI)
  • AAPG 34.07
  • TMDX 53.22
  • Support Level
  • AAPG $32.68
  • TMDX $119.20
  • Resistance Level
  • AAPG $34.31
  • TMDX $128.09
  • Average True Range (ATR)
  • AAPG 0.70
  • TMDX 7.76
  • MACD
  • AAPG -0.04
  • TMDX -0.37
  • Stochastic Oscillator
  • AAPG 0.00
  • TMDX 36.76

About AAPG Ascentage Pharma Group International American Depository Shares

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: